Perifosine (KRX-0401)
| Brand Name: | |
| Generic Name: | perifosine |
| Code Name: | KRX-0401 |
| Company: | Keryx Biopharmaceuticals / Aeterna Zentaris |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Perifosine (news articles) is a novel anti-cancer agent that is being studied for its ability to inhibit Akt, a key signal transduction pathway. Akt is particularly important in the development of cancers, impacting programmed cell death, cell growth, cell differentiation, and cell survival. High levels of activated Akt are frequently observed in many types of cancer, and it is often activated in tumors that are resistant to other anti-cancer therapy. Perifosine does not appear to cause flu-like symptoms, decreases in platelets, or hair loss, which distinguishes it from other novel agents that inhibit the Akt pathway. The most common side effects include nausea, vomiting, diarrhea, and fatigue.
Clinical Trials:
For a list of clinical trials studying perifosine for the treatment of multiple myeloma, see ClinicalTrials.gov.
Web site for Perifosine: http://www.keryx.com/page.cfm?hmid=20&smid=30&pg=19
Related Articles:
- Perifosine Advances To Phase 3 Multiple Myeloma Clinical Trial
- ASH 2008 – Perifosine Effective Against Multiple Myeloma In Combination With Dexamethasone-Revlimid And Dexamethasone-Velcade
- Perifosine Combination May Be Effective In Relapsed/Refractory Multiple Myeloma (ASH 2011)
- Perifosine Combination Therapy Is Promising For Relapsed And Refractory Multiple Myeloma (ASH 2009)
- Beacon NewsFlashes – September 1, 2009
Keryx Pharmaceuticals has rights to distribute Perifosine in the U.S. and Canada. It is actually a product of Aeterna Zentaris (AEZS).
Leave a comment